Are Medical Stocks Lagging United Therapeutics (UTHR) This Year?

Company Performance - United Therapeutics (UTHR) has returned 3.9% year-to-date, outperforming the Medical sector average loss of 3.9% [4] - AnaptysBio, Inc. (ANAB) has returned 8.5% year-to-date, also outperforming the Medical sector [5] Earnings Estimates - The Zacks Consensus Estimate for UTHR's full-year earnings has increased by 4.6% over the past 90 days, indicating stronger analyst sentiment [4] - AnaptysBio, Inc.'s consensus EPS estimate for the current year has increased by 24% over the past three months [5] Industry Performance - United Therapeutics is part of the Medical - Drugs industry, which has lost 9.2% year-to-date, making UTHR's performance better than its industry average [6] - AnaptysBio, Inc. is part of the Medical - Biomedical and Genetics industry, which has moved -12.6% since the beginning of the year [7] Sector and Industry Rankings - The Medical sector is ranked 1 in the Zacks Sector Rank, which includes 16 different groups [2] - United Therapeutics is a member of the Medical - Drugs industry, ranked 63 in the Zacks Industry Rank [6] - AnaptysBio, Inc. falls under the Medical - Biomedical and Genetics industry, ranked 64 in the Zacks Industry Rank [7] Stock Ratings - United Therapeutics currently has a Zacks Rank of 2 (Buy) [3] - AnaptysBio, Inc. also has a Zacks Rank of 2 (Buy) [5]